BIOQuébec Appoints a New Chairman of the Board

MONTREAL, Feb. 28, 2013 /CNW Telbec/ - BIOQuébec is pleased to announce the 
appointment of Dr. Martin Godbout as chairman of the Board, replacing Mr. 
Gilles R. Gagnon, who held this position during the last 2 years. Mr. 
Godbout's appointment comes into force today. 
"Since its creation, BIOQuébec has played a key role as spokesperson of the 
biotechnology industry. It is with humility that I accept to collaborate, with 
all members of the Board, towards the development of strategies that will 
further the industry and promote the life sciences sector not only in Québec 
but abroad", stated Dr. Godbout. 
As director on BIOQuébec's Board for the last 2 years, Dr. Godbout also sits 
on several other Boards of biotechnology companies, foundations and Canadian 
scientific organizations. He is president of the MethylGene inc. and Génome 
Québec Boards and acts as director on the Boards of the following 
organizations: Acasti Pharma Inc., AmorChem Inc., AngioChem Inc., AsmaCure 
Inc., BioContact, the Fonds de recherche du Québec - santé (FQRS), Montréal 
In Vivo and the Fondation de l'Ataxie de Charlevoix. 
Dr. Godbout founded Génome Canada, and was its president and CEO for many 
years. Throughout his career, he sat on the Science and Technology Council of 
Québec and was a member of the Natural Sciences and Engineering Research 
Council of Canada. He also developed BioContact Québec, an annual symposium 
on biopharmaceutical partnerships. He held the position of senior 
vice-president of BioCapital, a major Canadian venture capital firm. Prior to 
this, he was CEO of Société Innovatech Québec, a technology investment 
fund. Dr. Godbout is an Officer of the Order of Canada and has received 
numerous awards in Canada and abroad. 
BIOQuébec's Board of Directors would like to thank Mr. Gagnon for his 
contribution to the association and wishes him much luck in his future 
About BIOQuébec 
BIOQuébec is a biotechnology and life science industry association 
representing nearly 100 member companies and R&D centres in Québec. The 
association works to create a positive business environment which fosters the 
growth of the life science industry, including access to capital and access to 
development and marketing partners, workforce development, a regulatory and 
competitive tax environment and the promotion of its members among various 
publics both in Québec and on an international level. 
Board of Directors 2012-2013 

    --  Dr. Martin Godbout
        President of the Board
        Corporate Director
        Hodran Consultants Inc.
    --  Mario Lebrun
        General Manager
    --  Michel Fortin
        Prevtec microbia inc.
    --  John-Michel T. Huss
        Corporate Director
    --  Yves Roy
        Corealis Pharma Inc.
    --  Andy Sheldon
        Medicago Inc.
    --  Cédric Bisson
        Venture Partner
        Teralys Capital Inc.
    --  Jean-Paul Castaigne
        Angiochem Inc.
    --  Richard Cherney
        Managing Partner
        Davies Ward Phillips & Vineberg, s.r.l.
    --  Claude Chevalier
        BIO-K + International Inc.
    --  Pierre Falardeau
        Oncozyme Pharma Inc.
    --  Jean Godin
        Chief Scientific Officer
        Novartis Pharma Canada Inc.
    --  Charles Grubsztajn
        Corporate Director
    --  Dr. Pavel Hamet
        Medpharmgene Inc.
    --  Grant Perry
        Vice-President, Public Affairs and Reimbursement
        GlaxoSmithKline Inc.
    --  Louise Proulx
        Corporate Director

Mario Lebrun BIOQuébec General Manager 450-781-3965


To view this news release in HTML formatting, please use the following URL:

ST: Quebec

-0- Feb/28/2013 14:00 GMT

Press spacebar to pause and continue. Press esc to stop.